Alimera Sciences, Inc. (NASDAQ:ALIM – Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 103,900 shares, a decline of 14.6% from the April 30th total of 121,700 shares. Based on an average daily trading volume, of 67,700 […]
Alimera Sciences, Inc. (NASDAQ:ALIM – Free Report) – HC Wainwright cut their Q3 2024 earnings per share estimates for shares of Alimera Sciences in a report issued on Thursday, May 16th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will earn ($0.01) per share for the quarter, down from their prior forecast […]
StockNews.com downgraded shares of Alimera Sciences (NASDAQ:ALIM – Free Report) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning. Separately, Maxim Group started coverage on shares of Alimera Sciences in a research report on Monday, March 25th. They set a buy rating and a $10.00 price […]
Alimera Sciences (NASDAQ:ALIM – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday. Separately, Maxim Group initiated coverage on Alimera Sciences in a research note on Monday, March 25th. They set a “buy” rating and a $10.00 price objective on the […]
StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report released on Saturday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a buy rating and set a $5.00 price objective on shares of Alimera Sciences in a research report on Monday, August […]